- |||||||||| ONCR-177 / Oncorus
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases: KEYNOTE-B73: Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (clinicaltrials.gov) - Jun 7, 2023
P1, N=66, Terminated,
N=132 --> 66 | Trial completion date: Jul 2028 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> May 2023; Terminated due to Oncorus portfolio reprioritization
- |||||||||| ONCR-177 / Oncorus
Enrollment closed, Combination therapy, Metastases: KEYNOTE-B73: Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (clinicaltrials.gov) - Jan 6, 2023
P1, N=132, Active, not recruiting,
N=132 --> 66 | Trial completion date: Jul 2028 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> May 2023; Terminated due to Oncorus portfolio reprioritization Recruiting --> Active, not recruiting
- |||||||||| ONCR-177 / Oncorus
Journal, PD(L)-1 Biomarker, IO biomarker: ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity. (Pubmed Central) - Jul 28, 2021
P1
The addition of systemic anti-PD-1 augmented the efficacy of mONCR-171, particularly for abscopal tumors. Based in part upon these preclinical results, ONCR-177 is being evaluated in patients with metastatic cancer (ONCR-177-101, NCT04348916).
- |||||||||| ONCR-177 / Oncorus
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: KEYNOTE-B73: Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors (clinicaltrials.gov) - Feb 12, 2021
P1, N=132, Recruiting,
Based in part upon these preclinical results, ONCR-177 is being evaluated in patients with metastatic cancer (ONCR-177-101, NCT04348916). N=71 --> 132 | Trial completion date: Oct 2027 --> Jul 2028 | Trial primary completion date: Jun 2023 --> Jan 2025
- |||||||||| ONCR-177 / Oncorus
[VIRTUAL] ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity () - Aug 18, 2020 - Abstract #IOS2020IOS_137;
ONCR-177 is armed with five transgenes selected for activation of antitumor immunity. Significant efficacy, survival benefit, and the elicitation of protective immunity were demonstrated in multiple syngeneic tumor models and warrant the clinical investigation of ONCR-177 in patients with metastatic cancer.
- |||||||||| ONCR-177 / Oncorus
mONCR-177 oncolytic virotherapy stimulates anti-tumor and anti-viral immunogenicity (Virtual Meeting II: E-Posters) - May 16, 2020 - Abstract #AACRII2020AACR-II_2967;
Treatment results in increased infiltrating immune cells, activation, and polyfunctional CD8+ T cells. These results highlight the dual modality mechanism of action of mONCR-177 treatment through direct tumor cell killing and immune stimulation through the antiviral response, and their enhancement by the immune stimulatory transgenes.
- |||||||||| ONCR-177 / Oncorus
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic AntiTumor Immunity () - May 9, 2020 - Abstract #ASGCT2020ASGCT_103;
In conclusion, ONCR-177/mONCR-171 potently activates local and systemic anti-tumor immune responses that result in durable responses, extended survival, and the elicitation of protective immunity. These encouraging preclinical data warrant the clinical investigation of ONCR-177 for the treatment of patients with metastatic cancer.
- |||||||||| ONCR-177 / Oncorus
ONCR-177, an oncolytic HSV designed to safely and potently activate systemic anti-tumor immunity (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1129;
In conclusion, ONCR-177/mONCR-171 potently activates local and systemic anti-tumor immune responses that result in durable responses, extended survival, and the elicitation of protective immunity. These encouraging preclinical data warrant the clinical investigation of ONCR-177 in patients with metastatic cancer.
|
